Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good points. Also funding is necessary for other trials.
I am pretty sure they will no sell any until the PIII Heat data is out. There is no need to as MT has repeatedly said they have enough cash until into next year.
More to come on tomorrow's CC.
P.S: Also a big pharma partnership sometimes requires equity sale.
Thanks..that's how I see it as well. Assuming they sell north of $10 per share, it would not be very dilutive to future earnings..(around 7.5 million shares ?). Total OS would be still relatively small for a $1 billion dollar revenue company
Surprised no comments yet on the $75M shelf filed today ?? TIA
biomanbaba,
congradulations !! You indeed have hit a jackpot in IMUC..Dr. Sanjay Gupta's coverage of IC-107 on CNN this weekend is being heard all over the world and there will be lot of buzz on IMUC next week...
I am loading up more tomorrow..
Awesome, IC-107 of IMUC covered on Sanjay Gupta CNN..see below
SANJAY GUPTA MD
Brain Cancer Vaccine; Forensic Imaging; Visions of Greatness
Aired August 11, 2012 - 16:30 ET
THIS IS A RUSH TRANSCRIPT. THIS COPY MAY NOT BE IN ITS FINAL FORM AND MAY BE UPDATED.
DR. SANJAY GUPTA, HOST: Hello. And thanks for being with us.
Lots to get to today including new technology that can help you separate the real from the fake when it comes to photos and PhotoShopped magazine covers. It's remarkable technology. We want to see if you can spot the difference.
Also, we're going to meet the first ever blind Olympic athlete now helping visually impaired children to get in the game.
But first, a look at something I find fascinating under the microscope. A new vaccine used to treat brain cancer is showing promising results.
(BEGIN VIDEOTAPE)
GUPTA (voice-over): It was back in March that Leila Valentine's husband first saw the signs. Leila chalked it up to being tired, having two small kids will do that. But her husband James insisted something wasn't right.
LEILA VALENTINE, CANCER PATIENT: So he was, you know, asking me questions and he goes, when is our kids' birthday? And I have no idea. And then he's like, no. Something is wrong. So he's like, no mother will forget their kids' birthday.
GUPTA: It turns out James' instincts were spot on. Leila's diagnosis? Glioblastoma, or GBM, it's the most common and most aggressive type of brain tumor.
DR. KEITH BLACK, NEUROSURGEON: It destroys our ability to see, our ability to speak, ability to move, remember. It destroys the very essence of who we are.
GUPTA: Like me, Dr. Keith Black is a neurosurgeon. He heads the Department of Neurosurgery at Cedar Sinai Medical Center in Los Angeles.
BLACK: It can grow within a matter of weeks. If from the time of diagnosis to death, if one does not have any treatment, that time can be as short, you know, as two to three months.
GUPTA: Even with the best standard of care no one beats this. Most patients die within 12 to 15 months of diagnosis.
Leila was diagnosed with a left frontal glioblastoma, grade four. VALENTINE: Yes. So it's devastating but I have my two young kids and that I think about so that was it, so I'm like I'm going to do it for my kids, fight for my kids.
GUPTA: Leila was admitted to the hospital on March 7th, the very next day a surgeon, a member of Dr. Black's team, took out as much of the tumor as he could. Then came six weeks of radiation therapy and chemotherapy. After that, something new, an experimental treatment, a vaccine against cancer.
BLACK: One of the strongest defenses we have against disease is our immune system. One of the first things that a brain tumor has to do in order to survive in the brain is that it has to make itself invisible to the immune system.
GUPTA: The experimental drug isn't like a flu vaccine. It doesn't keep you from getting cancer. It uses cells from your own body to encourage your immune system to mount a targeted aggressive defense.
BLACK: We had 16 patients that were newly diagnosed with this glioblastoma multiform.
GUPTA: Typically without the vaccine, only 12 percent of patients would make it to the five-year mark. This small group, 16 patients, did more than three times better.
BLACK: All of the 16 patients, six of the 16 are alive and disease free, three of those six are alive and disease free out past five years.
GUPTA: We met two of those three patients, Mary Wong Lee and Michael Wolfe.
MARY WONG LEE, RECEIVED ICT 170 CANCER VACCINE: When I tried to spell for him I think he realized there was something not right.
MICHAEL WOLFE, RECEIVED ICT-170 CANCER VACCINE: Went to work with a bad headache, had a seizure at the office, collapsed on the floor, called the ambulance, got to the hospital within five minutes.
GUPTA: Mary is now cancer free. No evidence of disease. At five years.
Michael? Six.
Dr. Christopher Wheeler is a research scientist at the neurosurgical institute at Cedar Sinai.
DR. CHRISTOPHER WHEELER, RESEARCH SCIENTIST: We take blood from the patient and change them into, from kind of nondescript blood cells into highly specific immune cells which are really good at jump- starting the immune system.
GUPTA: The vaccine is injected into the patient's armpit. It migrates to the lymph nodes and activates T cells in the blood stream. The T cells then recalculate to the glioblastoma, and initiate a calculated response from the body's immune system, killing both the tumor cells and cancer stem cells.
BLACK: And what we've learned about cancer is that it really doesn't behave like a human colony. Cancer behaves more like a termite colony. So, you have the queen termite that keeps making the offspring much like trying to get rid of termites in your house. You want to kill the queen cell or the queen termite or the cancer stem cell.
GUPTA: In the next stage of Dr. Black's study, half the patients are receiving the vaccine. Half are getting a placebo, in addition to standard chemotherapy and radiation. Neither Leila nor the doctors know what group she's in. But she's optimistic.
VALENTINE: I can't get down or else, you know, I'll go down, too. So I have to stay confident. I feel really good. Thank God. I really do. Yes.
(END VIDEOTAPE)
GUPTA: It's worth pointing out Dr. Black's vaccine isn't the only one out there. This general approach of ramping up the immune system in a targeted way is one of the most promising approaches to fighting cancer.
There's another brain cancer vaccine. It's known as CDX 110. It has also had promising results and is in phase three clinical trials. The last step before the FDA can consider whether it works and whether it's safe enough to make it widely available. We'll keep you posted on developments.
GUPTA: Up next, do you ever wonder which photos in magazines are PhotoShopped? I'm going to show you new technology that can help you detect a fake.
(COMMERCIAL BREAK)
(BEGIN VIDEO CLIP)
GUPTA (voice-over): In the magazine aisle, does it seem like the world is full of extremely beautiful people? Movie stars, actors, singers. If you're anything like me, you sometimes wonder what do these people look like in real life. It may come as no surprise but in a lot of cases, the photos are fake.
I recently met a man who will make you look at those covers in a whole new way. He created forensic imaging software to separate facts from fiction.
(on camera): Let me ask you, just generally speaking, how do you distinguish, I mean, extreme, you know, sort of touching up versus innocuous or minimal?
HANY FARID, PROFESSOR OF COMPUTER SCIENCE, DARMOUTH COLLEGE: Yes, you know, it's a gray area. I can tell you what is innocuous and minimal and I can tell you what is absolutely extreme. Those are easy to categorize. Everything in the middle is a little tricky. And so, that's why we sort of wanted to set out to build something that is very objective. If you legislate this or even try to control it internally as a publisher, it's fairly subjective. What one person may think is extreme is very different than another person. So, what we want to do is just actual vote basically. But you know, you can't do that practically. So, what the mathematics lets you do is effectively say this is what the average person will think.
That sort of takes away some of the subjection notion of this and I think it's more fair to the publisher and is more informative to the public.
GUPTA: So, what would it look like, you know, I was leafing through a magazine, I mean, the legislation goes through in this technology is in place?
FARID: Yes. So, think warning label on a cigarette pack. There would be a small box, small circle, something that's nicely engineered. That is a number between, say, one and five and the five means this person looks nothing like this in real life. One means this is a legitimate image and everything else in between is gradations.
GUPTA: Let's look at what you're talking about. The first one is an image of you.
FARID: Right.
GUPTA: And you've given yourself several trips to the gym.
FARID: I hit the gym pretty hard here. Yes. So I pumped myself up. This is not hard to do in any standard photo editing software.
And on the right what you se is the heat map tells you what has actually changed and by how much.
GUPTA: Bicep, there's --
FARID: Yes, the shoulders, the arms, the chest, the legs. And this is about a three on our scale. It is really, I looked quite different in terms of, now the face looks about the same, but the body actually looks quite different.
GUPTA: That's interesting. If that is a three, you do wonder what even higher numbers are.
But I think we have another one close up of I guess a woman who is a little bit older. She looks happy. She is attractive. What happened here?
FARID: Right. This is a great photo of (INAUDIBLE) coauthor in this work made. So the original is on the right and the other is on the left. This is done in most fashion magazines and advertisements, which is you remove all wrinkles, blemishes over the face. You can see he did a very good job on this -- a really good rendition. This is a little bit over a three. The reason why it's not a four or a five is because if you look at the structure of her face, it's basically the same. It hasn't been thinned. It hasn't been expanded. The eyes are about the same size. The mouth, nose are all the same.
So, really, you can see that we leave room for the really much more extreme which tells you there are much more extreme versions of this.
(END VIDEOTAPE)
GUPTA: Well, the magazine industry has long been split on the subject of retouching photos. But "Seventeen" magazine took a big step and recently said it's never going to change girls' bodies or face shapes in photos and will only include images of real girls and models who are healthy. It's quite extraordinary and the announcement is thanks to a 14-year-old girl named Julia Bluhm who started this petition urging the magazine to change.
And we're delighted to have her on the show and now she joins us from Maine.
Thanks for joining us, Julia.
JULIA BLUHM, "SPARK A MOVEMENT" BLOGGER: Thank you.
GUPTA: Yes, I want to congratulate you first off on being such an influential voice. You're so young, just 14 years old but obviously passionate about this issue. My understanding is you started this petition after hearing your friends -- essentially complain about how they look during ballet lessons.
Tell me about that. How did this start for you?
BLUHM: Well, I definitely heard it from my friends. My friends weren't very happy with how they looked I guess. And I blog for an organization called SPARK Summit and we were trying to figure out why that was. I think it's from the media and the PhotoShop that's used in the media because girls try to compare themselves to images that are impossible to be like.
GUPTA: You know, I work in the media as you know, and I'm really interested in this issue and also the fact that you were able to get a major publication to change their policy. What was it like? I mean, was that a tough battle? I mean, how did it go back and forth?
BLUHM: Well, at the very end of April, I went to New York and we held a mock photo shoot in front of "Seventeen" and they invited us to go up there and meet with Ann Shoket. That was when we first -- like when they first started listening to us and we met with Ann Shoket for about an hour and talked about how important it is to feature real girls in their magazine. They agreed with us. They said they'd get in touch with us.
For a while they -- we weren't in touch with them for a while, but then when we found they had published a page in their magazine talking about the issue PhotoShop, and saying that they are not going to photo shop it was really exciting.
GUPTA: You're so eloquent, I should say, as a 14-year-old. I have young gals myself and they could be a good model for them. Thanks so much, Julia, for being on our program.
BLUHM: Thank you.
GUPTA: OK. Take care. Coming up, we're going to check in with Tiffany Burke. Remember her? She is the one who decided to have a baby for her brother and sister-in-law. It's a remarkable story. They've got big news to share.
Stay with us.
(COMMERCIAL BREAK)
GUPTA: This summer we introduced you to a remarkable family story. Take a look at this image here.
You've got Natalie and her husband James. Then James' sister Tiffany and her husband Sean. What's remarkable in all this is that Tiffany is carrying a baby for Natalie and James. Again, James is her brother.
When we met they had just found out Tiffany was pregnant with twins. She's 20 weeks along now and they just got some pretty exciting news.
(BEGIN VIDEO CLIP)
UNIDENTIFIED FEMALE: Today, we are here for ultrasound to find out what is in this belly. We're going to find out if we're having a boy or girl, two girls, two boys.
(CROSSTALK)
UNIDENTIFIED MALE: Wow.
UNIDENTIFIED FEMALE: I love it.
UNIDENTIFIED MALE: We found out. What do you think?
UNIDENTIFIED MALE: Two boys.
UNIDENTIFIED MALE: Two boys.
UNIDENTIFIED MALE: Two boys. I need your help with the ball games.
UNIDENTIFIED MALE: Everything looking good still?
UNIDENTIFEID MALE: Yes. Real healthy.
(END VIDEO CLIP)
GUPTA: James is a little speech les there in that video. Joining us now is Natalie, James, Tiffany, and Sean. Two boys. As a father of three girls I got to say, wow. That is quite something. You know, guys, we had a chance to talk a few times in the past.
Natalie, let me start with you. You've obviously had some time to digest the fact that you're going to have three boys in the house. What was it like for you when you found that out and also again that Tiffany is carrying those boys for you?
NATALIE LUCICH, BIOLOGICAL MOM: This was kind of what I thought we were going to have. I was so excited. Basically we have our own sports team at home. I think Hunter is going to be a great big brother. You know, they're all going to be so close. We're so excited for that.
GUPTA: I can only imagine. I think for all of you there has to be a feeling of this is really settling in.
James, you're preparing for baseball games. I mean, when you hear this, has a weight been lifted off your shoulders and you have the news of this growing, healthy family despite the fact that Natalie was not able to carry?
JAMES LUCICH, NATALIE'S HUSBAND: Yes. In that aspect, yes. It has been a huge weight on her shoulders. But just so excited to know that our family is going to get bigger and to -- they're so healthy and it's just so exciting.
GUPTA: Yes. And, Tiffany, I think the last time we spoke, you were having pretty significant morning sickness. How is that going for you? How has the pregnancy been over all?
TIFFANY BURKE, SURROGATE MOTHER: Well, we've been really lucky with the pregnancy over all because the boys are growing just honestly perfectly, how they should be. They're really strong and healthy and they're within a couple days of each other growth wise. I'm still sick -- but I just keep telling myself it's not permanent. You know, the worst case scenario I go to nine months and the best case scenario maybe I'm done tomorrow or so. You just never know I guess.
GUPTA: Sean, you've been through this before as well. I mean, you know, with Tiffany being pregnant. I mean, how is this different for you emotionally? Do you think about it differently?
SEAN BURKE, TIFFANY'S HUSBAND: You know, I really don't. That's been asked a lot from friends and family. It's -- all I really care about right now is her well being, and my two boys, raising them correctly. But I don't think anything emotionally too much about the fact that, you know, these babies are going to be going to James and Natalie because they're still going to be in our lives down the road. So, yes.
GUPTA: And you guys obviously are very close and all the more close for what you're going through right now.
UNIDENTIFIED FEMALE: Yes. GUPTA: We're going to keep checking in. This is a remarkable story with so much feedback from our viewers about all of you. So, thanks for sharing.
J. LUCICH: Thank you.
S. BURKE: Thank you.
T. BURKE: Thank you.
GUPTA: And up next, a loss of sight but never a loss of vision. We'll take you to a summer camp for blind children who want to play competitive sports.
(COMMERCIAL BREAK)
(BEGIN VIDEOTAPE)
UNIDENTIFIED FEMALE: Good morning, Camp Abilities.
GUPTA (voice-over): Every day at Camp Abilities starts the same way, with care to share.
UNIDENTIFIED MALE: Have seven more shots on the basketball court last night, including three in a row.
(CHEERS)
UNIDENTIFIED KID: I ran three miles on the (INAUDIBLE) bike.
(CHEERS)
UNIDENTIFIED FEMALE: I did my first back flip on the rings at gymnastics.
(CHEERS)
GUPTA: All these children are visually impaired. And they've come to Camp Abilities for a one-week developmental sports camp. Their inspiration this year is Marla Runyan who was diagnosed with Stargardt disease. It's a form of juvenile onset macular degeneration. She was diagnosed when she was just nine years old.
MARLA RUNYAN, DIAGNOSED WITH STARGARDT'S DISEASE AT AGE 9: We all know, for everybody whether sighted or not, you know, physical exercise activities, sports, think about what a role that plays in your life. Running became my choice of sport after I kind of abandoned soccer and I had such trouble seeing the ball, obviously, so I went out for my high school track team.
GUPTA: And boy could Runyan run. After running track and field in high school and college, she turned pro, eventually becoming the first legally-blind athlete to compete in the Olympic Games. Runyan says she was able to reach her full potential by competing against the best athletes in the world.
And now she's giving these campers their first taste of competitive sports.
RUNYAN: Camp Abilities to me is all about empowering kids and teaching them what they can do and giving them opportunities that they are not otherwise available to them at public school or after school programs.
GUPTA: And there's a lot to choose from -- sports like beat baseball, goal ball. They learn to ride bikes, practice judo, and of course run track.
RUNYAN: When my vision changed, but my desire to be in sports never changed. So I just stuck with it.
GUPTA: Just like the camp's mantra says. A loss of sight doesn't have to mean a loss of vision.
RUNYAN: Our motto for Camp Abilities is believe you can.
KIDS: I believe.
(END VIDEOTAPE)
GUPTA: "Chasing Life" today. More Olympic inspiration. I think you're going to like this. Older athletes., here is a picture that caught my eye.
Bulgarian gymnast Yordan Yochev. He's 39 years old. This is his sixth Olympics. Keep in mind, this is a young man's game and he's twice the age of most of his rivals but he still finished eighth on the rings out of 68 competitors.
And at 39, he is just a kid to some of the other Olympians like Anne van Olst from Denmark. She is 50.
And Joan Tomas Roca from Andorra, a trap shooter. He's 57.
Then we have the oldest athlete in the games. Hiroshi Hoketsu, an equestrian rider from Japan is 71 years old. Guess what? Back home they call him the hope for old men. I love that.
We can't all be world class athletes but if you do exercise you can maintain strength, endurance, and skill well into middle age and far beyond as you just saw.
That's going to wraps things up for SGMD. Stay connected with me at CNN.com/Sanjay, let's keep the conversation going on Twitter @SanjayGuptaCNN.
Time now to get you a check of your top stories in "THE CNN NEWSROOM".
Good thinking..FWIW, I have 250 of Jan 14 4's at 0.95...I am 50/50 between common and options.
Here is the link.
http://dockets.justia.com/docket/new-jersey/njdce/3:2012cv04848/277856/
It's a tort and very likely to be a non-event considering the insurance Celsion already has for such situations.
Very good opportunity to average down, IMHO..the PPS will be north of $3 as we approach the Aug 14th CC..
I hope MT shares some info on Aug 7th CC..at least let some with lot more degree of enthusiasm speak..lol..
Got it ! So basically if the PPS is still under $4 come Jan 2014, for whatever reason, he still retains the shares but gettng some profits off the covered calls now.
My question is, for such a short term gain (90 cents per call), why is he risking a hugh profit on his commons when very likely we will be much above $4 come Jan 2014 ? Unless...the world ends before then..
P.S: I was told that Hedgies often have policy not to hold shares for more than 1 year..may be his horizon is no later than end of this year. But hard to imagine someone bailing out before PIII results are out unless they see a very less chance of it being successful.
On the other hand, whoever bought 10k calls is investing a heck of a money on the CLSN's future..it's not a chump change..as they say, for every seller, there is a buyer..
I don't understand. Assuming the seller sold covered calls, he cannot realize the profits until the option expire under $4, right ? So this is still an 'unrealized' gain..
I think Aug 7 might bring some additional news. The CC will be interesting and MT though not exactly a inspiring speaker might share a thing or two on trial progress...at least their confidence level should be high..
I honestly think same time next year, we all will be laughing how ridiculous the pps was and how many missed an opportunity of their life time....all IMHO...
FWIW, I loaded up 200 contracts today (Jan 14 4's)...
I just bot 200 Jan 14 4 contracts myself after I saw that crazy volume today...
Good analysis. So you think piii results will show higher than 33% improvement PFS over the control arm ? This is what the market is expecting. It would be nice to see 45 to 50% statsig
Great find ! We will be inching up back to 3.5 level soon..
Now the talk of 2015 and secondary etc is like skeletons out of the woodworks...whatever happened to short term catalysts including PII data to be released by early 2013 ? Ayer Capital is not the one to hold shares until 2015...I see continued upward trend..
Great News ! Just saw Ayer Capital has 2 million share stake in IMUC..they must have taken position recently. They are the largest holders as of now... expecting some price movement in near future..
I listened to CLSN's CC's again today -- more than I can remember and sometimes feels like you start to read between the lines..LOL
I have a strong feeling with CLSN that their reason for optimisim is they KNOW they'll hit the marks. I am not saying they have access to numbers as they're not suppose to have, but with the data they can look at -- THEY SEEM TO KNOW. Of course they are walking the legal tightrope in what they can say, but I get the feeling it's all they can do to keep from blurting out "I GUARANTEE, THERE'S NO WAY THE NUMBERS WILL NOT BE GOOD IF NOT GREAT."
September will be another big milestone as DMC will vote after an interim look. Who knows they might even call a halt...
bioman, would you know where to get the Q2 hedge fund reports ? Few links to Edgar is still showing 3/31/12. I am 'dying' to know who loaded what & how many as of June 2012 end..
Bought 5K at 3.63 FWIW..good opportunity, IMHO
ROFALMAO ! Another couple of days and we will know which funds loaded up CLSN Q2. Definitely this much of volume we have seen is not all retail buys...expecting $5 prior to Sept interim review by DMC
It's a simple math, watson, why pull calculus ?
Obviously you are a shorty...below $2 ? after all that CEO said about $1billion potential....$6 looong term...lol..dream on to get some shares el cheapo..aint gonna happen..
Bioman, you hit a perfect example, IMHO...IMUC chart will put the PCYC's to shame once the PII results come out. The multi-antigen based cancer immunotherapy is an open field that can be very effectively used for different types of cancers, starting with brain cancer that's most deadliest of them all. THe low cost of their vaccine platform is very compelling as well. I am waiting to see the June end funds report to see if Ayer Capital has loaded their boat,,,will be interesting nevertheless..
FWIW, I am sitting on 50k shares and 100 Jan 5 calls. For the common, I plan to wait out until FDA approval or $40 whichever comes first.. As you know, a big pharma partnership is a defacto stamp of approval which alone would take the pps past $15...
The drug delivery platform of CLSN is as unique as IMUC's..
LOL...hey, bioman, I was must kidding...thanks for all your support & insight
later... $10
0.40 but expect a good premium for my calls once we go past Q3..
I just got 100 Jan 5 call Agree, too good to pass
I still think you are low balling the pps. Big pharma partnership soon after the data is released will take it to 15 minimum, all IMHO
To be candid, your post of $40 on FDA approval doesn't make sense in light of your earlier post on pps approaching $20 into PDUFA data and doing only $350 million revenue first year. Where does this $40 come from ? A 20 point jump just on approval..
From PPS point of view, we will be closer to $20 once the results come out Q4 this year. The $1 billon market potential for this treatment will attract big pharma players driving the price probably higher. I see MDVN like move soon when it jumped from below 20 to 40+ in November last year and it's been parabolic since then....
Bioman,
If I may ask, what's your take on the PIII PFS data being poor, nothing spectacular and really fantastic ? While it's worth waiting this long purely based on the promising technology, MT has been all that inspiring; however I am clinging to his 'blockbuster' use in the CC's. You too see the same way ? TIA
The Jan 2013 calls will be very interesting as the PIII results will be in. That's where most of the premium will be...
oh...yeah...the 'sell off' would happen at $30 as well not far into future and that's too bad .....lol
This article is a total crap...'failed to meet success ?'. The author obviously is clueless..
The interim's p value was intentionally kept very high and the company repeatedly did say that they do not expect the interim look to hit the bar.
the author conveniently forgets to comment on DMC's unanimous recommendation to move forward.
Usually posters have less impact than Oral presentations. I expect him to reiterate what we already know on the efficacy but not whole lot as a surprise...but I am willing to go wrong...
Holding 25k
It's interesting that Ayer Capital bought sizable holding in Verastem end of 1Q this year.
Makes me more convinced on the value of IMUC...all these funds are waiting to pounce once we get listed on the big board.
? is AYer out ?